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Background-—Urinary 11-dehydro-thromboxane (TX)B2 has been described as a potential predictive biomarker of major adverse
cardiovascular events (MACEs) in high cardiac risk patients. This part of LTIMI (Leukotrienes and Thromboxane In Myocardial
Infarction) study aimed to evaluate the relationship between 11-dehydro-TXB2 and MACEs in patients with acute myocardial
infarction (AMI).
Methods and Results-—LTIMI was an observational, prospective study in 180 consecutive patients with AMI type 1 referred for
primary percutaneous coronary intervention. On admission and at follow-up visits (1 month, 1 year), 11-dehydro-TXB2 was
measured in urinary samples by using high-performance liquid chromatography–tandem mass spectrometry. The primary outcome
was occurrence of composite MACEs during 1-year after AMI. Left ventricular ejection fraction was assessed in echocardiography
on admission and at 1-year follow-up. Analyses of 11-dehydro-TXB2 (pg/mg creatinine) were performed on log-transformed data
and expressed as median with IQR (Q1–Q3). 11-Dehydro-TXB2 level on admission was 7.39 (6.85–8.01) and decreased at 1 month
(6.73, 6.27–7.12; P<0.001) and 1-year follow-up (6.37, 5.91–6.94; P<0.001). In univariate analysis, baseline 11-dehydro-TXB2 was
higher in patients with MACEs (n=60; 7.73, 7.07–8.60) compared with those without MACEs (n=119; 7.28, 6.68–7.79; P=0.002).
In multivariate regression model, 11-dehydro-TXB2 and 3 other variables (diabetes, multivessel disease, and left ventricular ejection
fraction) were found to be best 1-year cumulative MACE predictors with odds ratio for 11-dehydro-TXB2 of 1.58 (95% CI 1.095–
2.33; P=0.017) and area under the curve (in receiver operating characteristic analysis of 0.8). Baseline 11-dehydro-TXB2 negatively
correlated with both left ventricular ejection fraction on admission (R=0.21; P=0.006) and after 1 year (R=0.346; P<0.001).
Conclusions-—11-Dehydro-TXB2 predicts 1-year cumulative MACEs in AMI patients and provides prognostic information on the left
ventricular performance. ( J Am Heart Assoc. 2016;5:e003702 doi: 10.1161/JAHA.116.003702)
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T hromboxane (TX)A2 is a potent platelet agonist andvasoconstrictor1 produced mostly by platelets, which
play a pivotal role in thrombogenesis at sites of vulnerable
plaque and provide a strong rationale for blocking their
function in the setting of acute myocardial infarction (AMI).1,2
However, platelets produce only 70% of TX in human body,
and the remaining 30% is produced by extraplatelet sources
such as monocytes and macrophages and may increase in
acute inflammation.3 This unrecognized fact may translate
into the unacceptable rates of clinical events such as
myocardial infarction, cardiovascular death, and need for
repeat revascularization, despite proper antiplatelet therapy.
TXA2 is an unstable compound with short plasma half-life of
30 seconds and therefore is difficult to measure.4 TXA2 is
rapidly inactivated to TXB2 and further undergoes dehydro-
genation to 11-dehydro-TXB2.
5,6 The latter is a stable metabo-
lite excreted in urine, and its measurement provides a reliable
estimate of the total in vivo production of TXA2 including the
extraplatelet sources.7,8 11-Dehydro-TXB2 has been found to be
elevated in several atherothrombotic diseases and to correlate
with major adverse clinical events.9–14 However, none of the
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studies have evaluated the association of 11-dehydro-TXB2with
patients’ long-term outcomes in AMI.
The LTIMI (Leukotrienes and Thromboxane In Myocardial
Infarction) study was a prospective, observational study that
aimed to assess the relationship between arachidonic acid
derivatives and major adverse cardiovascular events (MACEs)
in patients with AMI. We report TX biosynthesis evaluated by
urinary 11-dehydro-TXB2 excretion during AMI and after
1-year observation period, analyzing its impact on patient’s
prognosis.
Methods
Study Population
The LTIMI study was conducted between July 2011 and
September 2014. The study personnel evaluated 254 con-
secutive patients with ST-segment elevation (STEMI) and non–
ST-segment elevation AMI (NSTEMI) who were transferred to
interventional cardiology reference center for urgent coronary
angiography and percutaneous coronary intervention (PCI).
Only patients with MI type I (atherothrombotic, spontaneous)
and symptoms lasting no longer than 24 hours were eligible
for the study. In the setting of NSTEMI, most of the patients
underwent immediate invasive strategy (0–2 hours) or early
invasive strategy (<24 hours of diagnosis); none underwent
delayed invasive strategy (within 24–72 hours of diagnosis) in
the setting of NSTEMI. All patients with STEMI received
immediate PCI without previous fibrinolysis.
Type of AMI was based on the Joint European Society of
Cardiology/American College of Cardiology Foundation/Amer-
ican Heart Association/World Heart Federation Universal
Definition15,16 by 2 cardiologists who were aware of all
patients’ clinical data including coronary angiography (CA)
findings. Patients naive to antiplatelets were treated with
300 mg non–enteric-coated aspirin and 300 to 600 mg of
clopidogrel in the ambulance or the emergency department. If
the patients were taking aspirin on a long-term basis, they
received a lower dose of 75 mg (not enteric coated); the same
was true for clopidogrel (75-mg dose was used). Exclusion
criteria were late presentation of AMI (>24 hours from first
symptoms), AMI other than type I, cardiogenic shock, history of
coronary artery bypass graft surgery (CABG), severe valvular
heart disease, symptoms of acute infection, asthma, chronic
obstructive pulmonary disease exacerbation, use of antileuko-
triene medications, chronic kidney disease, liver cirrhosis,
malignancy, patient’s refusal to participate in the study (<2% of
patients), and noncompliance. Patients who received antiplate-
let drugs other than aspirin and clopidogrel before or after PCI
or were enrolled in any other interventional trial were excluded
from the study. The latter was the most common exclusion
criterion. A study flow chart is presented on Figure 1.
Finally, 180 patients who gave written informed consent
were recruited to the study, and 171 completed the 1-year
follow-up period. The study protocol complied with the
Helsinki Declaration and was approved by the Jagiellonian
University ethics committee.
Baseline Characteristics
Data on comorbidities, demographic characteristics, and
history of presenting complaints were collected by research
staff. Standard laboratory tests were performed including
serial high-sensitivity troponin T measurements (hs-TnT,
Roche Diagnostics). Blood and urine samples were collected
from each participant before CA and stored immediately after
centrifugation at 70°C for further analysis.
TX Measurements
11-Dehydro-TXB2 was measured at the presence of identical
deuterated standard added to the urine sample before high-
performance liquid chromatography–tandem mass spectrom-
etry measurement, as previously described.17 Results are
expressed in picograms per milligram creatinine as natural
logarithms. Detailed methods are described in Supplementary
Materials.
Transthoracic Echocardiography
Standard transthoracic echocardiography was performed in all
patients on admission because of AMI and at 1-year follow-up.
Apical, parasternal, and subcostal views were used according
to current guidelines18 with use of the Vivid 7 ultrasound
system (GE Vingmed Ultrasound A/S). Left ventricular
ejection fraction (LVEF) was calculated by using Simpson’s
method. Global left ventricular dysfunction was defined as
LVEF <55%. For statistical comparisons, a patient’s LVEF was
stratified as slightly impaired (45–54%), moderately impaired
(30–44%), or severely impaired (<30%). Two experienced
cardiologists-echocardiographers assessed images indepen-
dently, unaware of 11-dehydro-TXB2 results.
CA and PCI
CA was performed by using the standard Seldinger technique,
with the patient under local anesthesia, via puncture of the
femoral or radial artery, with the use of typical diagnostic and
guiding catheters. Arterial access was selected at the
discretion of the operator. All patients were given the same
type of low-osmolar and nonionic iodinated contrast media
(Visipaque 320 GE Healthcare Inc). Immediately after CA, the
results were analyzed and patients were qualified for imme-
diate PCI with angioplasty and stent implantation of the culprit
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vessel or referred for urgent CABG. The type of stent and its
diameter and length were selected on the basis of angio-
graphic measurements assisted with digital quantitative
angiography (Axiom ZEE angiograph, computer software
VC21B; Siemens). Control angiography was performed after
stent implantation to document and assess obtained result.
Final Outcomes Measurements and Follow-up
Study outcome measurements
The primary outcome was occurrence of a composite MACE
that occurred during a 1-year follow-up period after AMI. This
composite MACE consisted of 8 events: recurrent myocardial
infarction, stroke/transient ischemic attack, cardiogenic
shock, pulmonary edema, nonfatal cardiac arrest, need for
rescue PCI or CABG, and cardiovascular death. If 2 MACEs
occurred in 1 patient (eg, recurrent MI and death in follow-up),
it was counted as 1 cumulative MACE. Definitions are
available in Supplemental Materials.
Secondary outcomes included (1) composite MACE at the
following time points: discharge from hospital and at 1-month
follow-up; and (2) LVEF measured on admission and at 1-year
follow-up.
Two cardiologists-echocardiographers adjudicated all
events independently and were blinded to the 11-dehydro-
TXB2 results while performing the clinical follow-up.
Figure 1. Study flow chart. CABG indicates coronary artery bypass graft surgery; NSTEMI,
non–ST-elevation myocardial infarction; PPCI, primary percutaneous coronary intervention;
STEMI, ST-elevation myocardial infarction.
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Follow-up
Patients were observed for a 1-year period after enrollment in
the study. Two visits were scheduled in the outpatient clinic,
at 1 month and 1 year after AMI. The data on the occurrence
of MACEs were collected by the research team and verified
based on either hospital discharge notes or family member
interrogation. Urine samples were collected at both visits for
11-dehydro-TXB2 analyses.
Statistical Analysis
Categorical variables were presented as counts (percentages),
whereas continuous variables were reported as meanSD or
median with IQR (Q1–Q3) depending on their distribution.
Urinary 11-dehydro-TXB2 data were naturally log-transformed
to approximate normal distribution for further analysis and
expressed throughout the text as median with IQR (Q1–Q3).
Assumption of normality was verified by using the Kol-
mogorov–Smirnov test. Categorical variables were compared
between MACE and non-MACE groups by using v2 test or
Fisher’s exact test, and continuous variables were compared
by using Student t test or Mann–Whitney U test as
appropriate. Correlations between variables were analyzed
by using Pearson’s or Spearman’s rank correlation, as
appropriate for the data distribution. For analysis of
11-dehydro-TXB2 in urine at different time points during
follow-up, 1-way ANOVA for repeated measures and the post-
hoc Tukey test were used.
For comparisons of LVEF with 11-dehydro-TXB2 levels, the
Kruskal–Wallis test was used with post-hoc Mann–Whitney
comparison adjusted with the Bonferroni correction.
Associations between 11-dehydro-TXB2 and MACEs
after PCI were estimated as an odds ratio (OR) and
corresponding 95% CI) by using univariate logistic regres-
sion analysis.
The associations of 11-dehydro-TXB2, cardiac biomarkers,
inflammatory parameters, and composite MACE were tested
after division into quartiles according to the 11-dehydro-TXB2
distribution. The diagnostic performance of 11-dehydro-TXB2
for the prediction of cumulative MACEs was evaluated by
using receiver operating characteristic curve analysis, and the
optimal threshold was based on the point of combined best
sensitivity/specificity results.
Finally, the association between 11-dehydro-TXB2 and
cumulative MACE incidence was evaluated with use of the
multiple logistic regression. Explanatory variables were cho-
sen in stepwise approach on the basis of the Akaike
information criterion based on the prespecified baseline
clinical and laboratory characteristics. Variables included age,
sex, body mass index, smoking (pack-years), past history of
MI, diabetes mellitus, hypertension, time from symptoms to
PCI, multivessel disease, LVEF during hospitalization, maximal
TnT level, C-reactive protein (CRP), glomerular filtration rate,
and 11-dehydro-TXB2.
All statistical analyses were performed by using R
software, version 3.1.2 (R Development Core Team [2009].
R: A language and environment for statistical computing. R
Foundation for Statistical Computing). P-values <0.05 were
considered statistically significant.
Results
Patients
One hundred eighty patients with type I AMI (50.6% with
STEMI and 49.4% with NSTEMI) who underwent CA on
hospital admission were found to be eligible for the study
(Figure 1). Time from symptom onset to the PCI was
9.236.71 hours. Mean age of the study cohort was
66.4811.87 years, and men outnumbered women (69.4%
versus 30.6%). Detailed demographic parameters and cardio-
vascular risk factors are shown in Table 1. On admission, all
patients had elevated hs-TnT, 52.8% presented with increased
leukocyte count >104/lL, and 46.1% had high-sensitivity CRP
elevated above the normal range. In 164 patients (91.1%), PCI
was performed, and 16 patients (8.9%) required surgical
revascularization (CABG). The majority of the patients (n=117;
65%) had at least 2-vessel disease, and mean LVEF measured
on admission was 44.713.8%.
Aspirin and clopidogrel were administered to all patients
at least 30 minutes before the urine sample collection. In
the studied group, 54 (30%) patients received aspirin on a
long-term basis before admission, and 11 (6.1%) additional
patients were taking clopidogrel. By discharge from the
hospital, all patients were taking aspirin, and 94.4% were
taking clopidogrel (except 10 patients scheduled for CABG).
Follow-up MACEs
At 1-year follow-up, the composite MACE appeared in 60
patients (33.3%), and of this group, 14 (7.8%) patients died. All
MACEs with their time occurrence are listed in Table S1.
Patients with MACEs compared with patients without MACEs
more frequently had multivessel disease, diabetes, and
peripheral artery disease, whereas there were fewer current
smokers. Additionally, in the MACE group, patients presented
with higher admission levels of glucose (7.85 [6.27–10]
versus 6.8 [5.8–8.3] mg/L; P=0.012) and lower triglyceride
levels (1.05 [0.81–1.56] versus 1.3 [0.94–1.67] mmol/L;
P=0.044). Comparisons of clinical and laboratory data are
shown in Tables 1 and 2.
The baseline LVEF was 44.7113.79% and increased at
1-year follow-up to 55.6810.62% (P<0.001), being lower at
both time points in patients with MACEs.
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Urinary TX Metabolite Excretion
All analyses were performed on log-transformed data. The
highest level of 11-dehydro-TXB2 was on admission, 7.39
(6.85–8.01), and decreased in the follow-up after 1 month to
6.73 (6.27–7.12) and after 1 year to 6.37 (5.91–6.94) pg/mg
creatinine. The decline was statistically significant between
each follow-up level (1 month and 1 year) compared with the
admission sample (P<0.001; Figure 2).
Patients taking aspirin and/or clopidogrel on a long-
term basis had lower admission 11-dehydro-TXB2 (7.12
[6.68–7.59] versus 7.57 [6.94–8.15] pg/mg creatinine;
P=0.005).
11-Dehydro-TXB2 levels were higher in STEMI patients than
in those with NSTEMI (7.59 [6.97–8.14] versus 7.24 [6.55–7.7]
pg/mg creatinine, respectively; P=0.013). There were no
differences in 11-dehydro-TXB2 levels adjusted for age and sex.
Table 1. Baseline Characteristic of the Study Group by MACE and Non-MACE Subgroup
Characteristic Overall (n=180) MACE (n=60) Non-MACE (n=120) P Value
Demographic characteristics
Age, y (%)
<55 36 (20) 8 (13.3) 28 (23.3) 0.126
55–75 98 (54.4) 32 (53.3) 66 (55)
>75 46 (25.6) 20 (33.3) 26 (21.7)
Female sex 55 (30.6) 22 (36.7) 33 (27.5) 0.277
Body mass index, kg/m2 (%) 0.877
Normal weight (18.5–24.99) 60 (33.3) 19 (31.7) 41 (34.2)
Overweight (25–29.99) 76 (42.2) 25 (41.7) 51 (42.5)
Obesity (>30) 44 (24.4) 16 (26.7) 28 (23.3)
Medical history
Hypertension, n (%) 128 (71.1) 46 (76.7) 82 (68.3) 0.323
Diabetes mellitus, n (%) 61 (33.9) 33 (55) 28 (23.3) <0.001
Dyslipidemia, n (%) 147 (86.5) 50 (89.3) 97 (85.1) 0.608
Myocardial infarction, n (%) 48 (26.7) 21 (35) 27 (22.5) 0.108
TIA/stroke, n (%) 13 (7.2) 5 (8.3) 8 (6.7) 0.762
PAD/claudication, n (%) 37 (20.6) 18 (30) 19 (15.8) 0.043
Family history of CAD, n (%) 78 (43.3) 29 (48.3) 49 (40.8) 0.425
Current smoker, n (%) 68 (37.8) 16 (26.7) 52 (43.3) 0.044
Clinical evaluation
Diagnosis 0.792
NSTEMI, n (%) 89 (49.4) 31 (51.7) 58 (48.3)
STEMI, n (%) 91 (50.6) 29 (48.3) 62 (51.7)
CAD, n (%) <0.001
1-Vessel disease 63 (35) 9 (15) 54 (45)
2-Vessel disease 59 (32.8) 19 (31.7) 40 (33.3)
3-Vessel disease 58 (32.2) 32 (53.3) 26 (21.7)
LVEF during AMI, n (%) 0.002
Normal (≥55) 55 (30.6) 11 (18.3) 44 (36.7)
Mildly impaired (45–54) 45 (25) 14 (23.3) 31 (25.8)
Moderately impaired (30–44) 57 (31.7) 20 (33.3) 37 (30.8)
Severely impaired (<30) 23 (12.8) 15 (25) 8 (6.7)
AMI indicates acute myocardial infarction; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular event; NSTEMI, non–ST-elevation
myocardial infarction; PAD, peripheral artery disease; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack.
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TX Correlations
Baseline 11-dehydro-TXB2 correlated weakly with maximal
peri-AMI levels of cardiac damage biomarkers (creatine kinase
maximum [R=0.17; P=0.03], hs-TnT [R=0.19; P=0.01]).
11-Dehydro-TXB2 also correlated with inflammatory parame-
ters (white blood cell count >109103/lL [R=0.23; P=0.002],
high-sensitivity CRP [R=0.31; P<0.001]). Both white blood cell
count (9.46; 7.92–11.09 in Q1 versus 11.52; 9.34–14.51
9103/lL in Q4; P=0.007) and high-sensitivity CRP (1.22;
0.55–3.54 in Q1 versus 6.29; 1.29–23.4 mg/L in Q4;
P<0.001; Figure S1) were significantly elevated in the highest
quartile of 11-dehydro-TXB2 level.
Primary Outcomes Analysis
Baseline mean 11-dehydro-TXB2 measured during AMI was
higher in patients who experienced MACEs at 1-year follow-up
(7.73 [7.07–8.60]) compared with those who did not (7.28
[6.68–7.79]; P=0.002). Between the quartiles of 11-dehydro-
TXB2, the incidence of cumulative MACEs increased by 266%
in Q4 compared with the first quartile (OR 3.66 [95% CI 1.47–
9.13]) (Figure 3; receiver operating characteristic curve—
Figure S2).
In the multivariate analysis based on logistic regression,
11-dehydro-TXB2 and 3 other variables (diabetes, LVEF during
AMI, and multivessel disease) were found to be the best
predictors of 1-year cumulative MACEs (Table 3). In this
model, the increase in natural logarithm of 11-dehydro-TXB2
Table 2. Baseline Laboratory Parameters Characteristic of the Study Group on Admission
Parameter Normal Values Overall (n=180) MACE (n=60) Non-MACE (n=120) P-Value
hs-TnT on admission, lg/L <0.014 0.14 (0.06–0.33) 0.19 (0.05–0.46) 0.14 (0.06–0.28) 0.14
hs-TnT max, lg/L 1.25 (0.29–4.65) 0.92 (0.41–4.96) 1.28 (0.24–4.51) 0.88
CK-MB on admission, U/L 0–24 21 (15–42.3) 23 (16.8–42.3) 20.5 (15–40.8) 0.41
CK-MB max, U/L 66.5 (26–187) 52 (29.8–154.8) 71.5 (23–206.5) 0.76
CK on admission, U/L 0–190 182 (104–341.3) 188.5 (110.75–369.3) 179 (103–335) 0.4
CK max, U/L 623 (215–1756) 643.5 (282.3–1445.8) 605 (201.5–1816.5) 0.7
hs-CRP, mg/L ≤3.0 2.8 (1.1–6.4) 3.95 (1.21–7) 2.5 (1.05–5.7) 0.16
WBC, 9103/lL 3.8–10 10.1 (8.1–12.2) 10.3 (8.4–13.7) 10.1 (7.9–11.9) 0.26
RBC, 9106/lL 4.2–6.0 4.7 (4.4–4.97) 4.59 (4.1–4.9) 4.8 (4.5–4.99) 0.07
Hb, g/dL 14–18 14.2 (13.2–15.1) 14 (12.8–15.2) 14.4 (13.4–15.1) 0.28
PLT, 9103/lL 140–440 221.5 (181.8–263.3) 218.5 (164–257.3) 222.5 (188.5–264.3) 0.43
GFR, mL/min per 1.73 m2 >60 74.8 (56.6–87.8) 67.3 (55.42–84.9) 78 (57.1–88.2) 0.08
Creatinine, lmol/L 62–106 84 (76.8–103) 86.5 (78–104.8) 83.5 (75–101) 0.33
Glucose, mmol/L 3.4–5.6 7 (6–8.6) 7.9 (6.27–10) 6.8 (5.8–8.3) 0.012
TC, mmol/L 3.1–5.0 4.7 (4.06–5.52) 4.42 (3.64–5.22) 4.85 (4.18–5.6) 0.15
LDL, mmol/L <3.0 3.01 (2.4–3.9) 2.67 (2.0–3.6) 3.09 (2.5–3.9) 0.1
HDL, mmol/L >1.0 1.2 (1.01–1.39) 1.2 (1.04–1.45) 1.2 (1.01–1.37) 0.3
TG, mmol/L <1.7 1.2 (0.9–1.6) 1.1 (0.8–1.6) 1.3 (0.9–1.7) 0.044
CK indicates creatine kinase; CK-MB, creatine kinase isoform; GFR, glomerular filtration rate; Hb, hemoglobin; HDL, high-density lipoprotein; hs-TnT, high-sensitivity troponin T; hs-CRP,
high-sensitive C-reactive protein; LDL, low-density lipoprotein; MACE indicates major adverse cardiovascular event; PLT, platelets; RBC, red blood cell; TC, total cholesterol; TG,
triglycerides; WBC, white blood cell.
Figure 2. Urinary 11-dehydro-TXB2 excretion on admission
(baseline) and at 1-month and 1-year follow-up. Average
(points) and SD (whiskers) of 11-dehydro-TXB2 on admission,
at 1-month and 1-year follow-up expressed in log-trans-
formed values. *P<0.001.
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by 1 was associated with increased risk of developing MACEs
within 1 year after AMI by 58.1%. Prognostic capability of
11-dehydro-TXB2 and other variables for predicting MACEs is
presented on Figure 4 and has an area under the curve
related to receiver operating characteristic curve of 0.806.
Based on this multivariate model, we developed a mathemat-
ical formula for risk prediction, which is presented in Data S1.
When long-term aspirin treatment was included in the
regression analysis, it did not influence the results.
Secondary Outcomes Analysis
LVEF and 11-dehydro-TXB2 level on admission
11-Dehydro-TXB2 on admission inversely correlated with both
measurements of LVEF at initial hospitalization (R=0.21;
P=0.006) and at 1-year observation (R=0.346; P<0.001).
Patients with most severely impaired LVEF (<30%) during AMI
were found to have the highest levels of 11-dehydro-TXB2
compared with all others. 11-dehydro-TXB2 level on admission
was also a predictor of LVEF after 1 year; it was higher in
patients with impaired LVEF compared with patients with
normal LVEF (Table 4).
The 11-dehydro-TXB2 levels measured at 1 month and
1 year after AMI did not correlate with LVEF.
11-Dehydro-TXB2 and MACEs at hospital discharge and
at 1-month follow-up
Log-transformed 11-dehydro-TXB2 on admission was predic-
tor of cumulative MACEs for both time points: for discharge
MACEs (OR 1.499, 95% CI 1.007–2.253) and for 1-month
MACEs (OR 1.57, 95% CI 1.11–2.257). Therefore, the increase
in log-transformed baseline 11-dehydro-TXB2 by 1 increased
the risk of MACEs on discharge from hospital by 49.9% and by
57% at 1-month follow-up.
Figure 4. Receiver operating characteristic curve
for predictive value of the multivariate regression
model on the cumulative MACE occurrence at 1-
year follow-up after AMI. The multivariate regres-
sion model includes 11-dehydro-thromboxane (TX)
B2 on admission, diabetes mellitus, MVD, and
baseline LVEF. AMI indicates acute myocardial
infarction; AUC, area under the curve; DM, diabetes
mellitus; LVEF, left ventricular ejection fraction;
MVD, multivessel disease.
Figure 3. Cumulative MACEs risk in 1 year following AMI
according to 11-dehydro-thromboxane (TX)B2 quartiles on admis-
sion. The ranges of quartiles intervals (Q1–Q4) expressed as log-
transformed values of 11-dehydro-TXB2 in pg/mg creatinine.
Ranges of log 11-dehydro-TXB2 quartiles are as follows: Q1:
<6.85; Q2: 6.85 to 7.39; Q3: 7.40 to 8.01; Q4: >8.01 (pg/mg
creatinine). Top bars are the ORs for cumulative MACEs at 1 year
from AMI, whiskers indicate CIs. AMI indicates acute myocardial
infarction; MACE, major adverse cardiovascular event; OR, odds
ratio.
Table 3. One-Year Follow-up Cumulative MACE Occurrence
in Multivariate Analysis With 11-Dehydro-TXB2
Variable OR 95% CI for OR P Value
Diabetes mellitus 2.476 1.128–5.451 0.024
LVEF during
hospitalization, %
0.978 0.95–1.006 0.133
CAD
1-vessel disease Reference level
2-vessel disease 4.671 1.646–14.951 0.006
3-vessel disease 9.141 3.308–29.023 <0.001
Log 11-dehydro-TXB2
on admission, pg/mg
creatinine
1.581 1.095–2.329 0.017
CAD indicates coronary artery disease; LVEF, left ventricular ejection fraction; MACE,
major adverse cardiovascular event; OR, odds ratio; TX, thromboxane. Variables included
in the multiple regression model are: age, sex, body mass index, smoking (pack-years),
past history of myocardial infarction, diabetes mellitus, hypertension, time from
symptoms to percutaneous coronary intervention, multivessel disease, LVEF during
hospitalization, maximal troponin level, C-reactive protein, glomerular filtration rate, and
11-dehydro-TXB2.
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Discussion
In the present study we evaluated the association of systemic
11-dehydro-TXB2 production with clinical outcomes of
patients with AMI. There are 2 main findings of the study.
First, a higher urinary level of 11-dehydro-TXB2 on admission
because of AMI significantly increases the probability of
cumulative MACE occurrence at 1-year follow-up. Second, the
same biomarker predicts LVEF performance post AMI.
The first observation is in line with the previous studies by
Eikelboom et al in which 11-dehydro-TXB2 was found to be a
good predictor of MACEs in a high cardiovascular risk
population treated with aspirin.9,10 The risk of MACE occur-
rence in these studies, when 2 extreme quartiles of 11-dehydro-
TXB2were compared, was between 1.66 and 1.8 times higher in
the upper quartile. In the present study, univariate analysis
revealed 3.66 times (95% CI 1.47–9.13) higher MACE risk in
patients within the highest 11-dehydro-TXB2 quartile, com-
pared with those in the lowest quartile. Importantly, when these
data were reevaluated by using a multivariate analysis, the
confounding factors, such as demographic features, treatment
options, or main laboratory findings, did not influence perfor-
mance of urinary 11-dehydro-TXB2 as a predictor of MACEs in
AMI patients. Actually, in the multivariate model only 3 other
variables contributed to 11-dehydro-TXB2 predictive properties:
LVEF on admission, presence of diabetes mellitus, and multi-
vessel disease. This model proved to have a good prediction
capability with an area under the curve of 0.806 and OR for 11-
dehydro-TXB2 of 1.581 (95% CI 1.095–2.329), results similar to
those presented by Eikelboom et al.9,10
There are several causes responsible for increased TX
production in AMI. First, during the acute phase of AMI, more
platelets are released and overactivated.1,19 Newly formed
platelets beside their constitutive cyclooxygenase (COX)-1
expression, retain COX-2 activity contributing to additional TX
synthesis.1,2,11,20,21 Further, intense thrombotic and concomi-
tant acute inflammatory processes present in AMI induce TX
synthesis from sources other than platelets, mostly inflam-
matory (monocytes and macrophages) and endothelial cells.22
These cells produce TX mainly via the COX-2 pathway and
stimulate platelets despite their inhibition by aspirin.23 Aspirin
in small doses blocks irreversibly COX-1–dependent TX
production; however, inhibition of COX-2 pathway requires
much higher doses of aspirin.2
These mechanisms may contribute to elevated TX synthe-
sis and may overcome the aspirin suppression of COX-1
pathway during AMI.24 It also explains why in patients taking
aspirin on a long-term basis, 11-dehydro-TXB2 production is
still maintained.
Urinary excretion of 11-dehydro-TXB2 is assumed to reflect
systemic TX biosynthesis most accurately25 and, in contrast
to serum TXB2, can also detect the in vivo “extraplatelet” TX
production.
In a recent study by Frelinger et al, the authors proved in a
prospective study that patients presenting for diagnostic
catheterization with elevated levels of serum TXB2 had higher
incidence of MACEs despite aspirin treatment in a 2-year
observation period.26 It confirms the findings of the present
study and highlights the importance of residual TX production
by ASA suppressed platelets.
Extraplatelet pathways are described as responsible for
30% of 11-dehydro-TXB2 production27 and significantly
increase in inflammatory and prothrombotic processes—which
are present during AMI. Our findings support this hypothesis, as
increased production of 11-dehydro-TXB2 during AMI corre-
lated with inflammatory parameters: high-sensitivity CRP and
Table 4. Association of Urinary 11-Dehydro-TXB2 on Admission With Baseline LVEF During Hospitalization and at 1-Year Follow-up
Systolic LV Function n
Log 11-Dehydro-TXB2 on Admission, pg/mg Creatinine
P-Value Post-hoc*Median Range Q1 Q3
LVEF during hospitalization, %
Normal (≥55) 55 7.32 5.54–9.45 6.62 7.82 0.002 a
Mildly impaired (45–54) 45 7.1 4.35–9.66 6.71 7.67 a
Moderately impaired (30–44) 57 7.49 5.67–10.74 6.92 8.13 ab
Severely impaired (<30) 23 7.73 5.2–10.26 7.49 8.95 b
LVEF after 12 mo, %
Normal (≥55) 81 7.15 4.35–9.3 6.42 7.59 <0.001 a
Mildly impaired (45–54) 35 7.49 6.25–9.44 7.1 7.88 b
Moderately impaired (30–44) 21 7.73 5.67–10.13 7.27 8.68 b
Severely impaired (<30) 3 8.76 7.59–9.31 8.17 9.03 b
EF indicates ejection fraction; LV, left ventricular; Q1, quartile; Q3, quartile 3; TX, thromboxane.
*Results of post-hoc analysis. Groups identified with the same letter did not differ significantly.
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increased white blood cells. Further, 11-dehydro-TXB2 sub-
stantially decreased at both 1-month and 1-year follow-up
compared with the baseline measurements in the acute phase,
which cannot be solely explained by the long-term aspirin
treatment after AMI. This is in parallel with the recent study by
Cangemi et al, where the authors described TXB2 elevation in
patients with pneumonia and subsequent AMI.28
Results of the present study demonstrated that patients
with higher levels of 11-dehydro-TXB2 have decreased LVEF
during AMI and increased levels of baseline 11-dehydro-TXB2
predicted decreased LVEF at 1-year follow-up. This relation-
ship between elevated TX biosynthesis and reversible
myocardial dysfunction may suggest impairment of microcir-
culation and may play a pivotal role in the pathogenesis of MI.
Moreover, 11-dehydro-TXB2 on admission correlated with
maximal values of biomarkers of myocardial damage, such as
creatine kinase and hs-TnT, which confirmed the results of
Valles et al—that TXA2 was found to correlate with the
myonecrosis in nonresponding to aspirin-treated patients.29
Also, in a study by Nicolli et al, TXB2 production correlated
with the severity and extent of atherosclerotic changes in
coronary vessels despite aspirin treatment.30
In our study, we also found that 11-dehydro-TXB2 levels
were higher in STEMI patients compared with NSTEMI
patients, which can be explained by more intense inflamma-
tory response and a crucial role of myonecrosis in pathogen-
esis of STEMI compared with NSTEMI.31
Complementary to our findings, it has been described by
Nicolli et al that TXA2 measurement could be an independent
predictor of no-reflow syndrome following coronary interven-
tion, which probably contributes to the short-term complica-
tions after AMI and corresponds with our study findings.32
This could explain why patients with higher levels of 11-
dehydro-TXB2 had a higher incidence of cumulative MACEs in
a short-term follow-up after AMI (at hospital discharge and
1nmonth). However, these findings should be treated with
caution, as the number of cumulative MACEs was relatively
small at this time period.
To our best knowledge, no previous studies have examined
11-dehydro-TXB2 in AMI and its associations with future
MACEs and left ventricular performance. The strengths of the
present study include very low dropout of patients (3%) during
follow-up and strict inclusion criteria that made the studied
group homogeneous. We evaluated only patients assumed to
have AMI of type I who underwent PCI, whereas symptoms
lasted not longer than 24 hours. In this cohort of 180
patients, a relatively large proportion of patients had cumu-
lative MACEs at 1-year follow-up (60 patients), which enabled
us to draw conclusions on the 11-dehydro-TXB2 predictive
value as a biomarker. We used the most sensitive quantitative
assay of combined high-performance liquid chromatography–
tandem mass spectrometry. This is of great importance, as
several previous studies described problems with reliability
with the monoclonal antibody ELISA, which detects not only
11-dehydro-TXB2 but also an additional metabolite like 11-
dehydro-2,3-dinor-TXB2.
4
Limitations of the Study
This study is a single-center study with a limited number of
patients. The study group was sufficient to evaluate the
cumulative MACE outcomes but not large enough to evaluate
each different MACE complication separately; thus, they had to
be evaluated cumulatively. Being aware of this necessity when
developing the study protocol, we designed the LTIMI study to
evaluate cumulative MACEs as a primary outcome. Neverthe-
less, a future multicenter study is warranted to verify the
outcomes in a larger cohort of patients with AMI. Another
limitation of the study is that some patients were taking long-
term aspirin treatment before study enrollment. This bias
imposed by long-term treatment with aspirin was, however,
balanced by the fact that all patients received aspirin imme-
diately when suspected of having AMI and at least 30 minutes
before sample collection for further analysis. After oral intake
of uncoated aspirin, it reaches its concentration peak in blood
at 30 minutes. This approach represents more of a “real-life
scenario” and, importantly, long-term aspirin treatment did not
influence the statistical models of 11-dehydro-TXB2 perfor-
mance as a biomarker. Finally, several other factors not
evaluated in this study could influence 11-dehydro-TXB2
measurements such as a patient’s genetic variability of TX
production or TX receptor synthesis and turnover. This study
also did not aim to assess the interindividual resistance to
aspirin or other antiplatelet drugs, which may also influence the
TX production and MACE incidence.
In conclusion, 11-dehydro-TXB2 measured in AMI patients
is an independent predictor of major cardiovascular outcomes
that occur during the first year after the incidence and may
provide prognostic information on left ventricular perfor-
mance. These findings shed additional light on the patholog-
ical role of TXA2 in AMI complications.
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SUPPLEMENTAL MATERIAL 
 
 
Supplemental Methods  
 
 
MACE Definitions 
 
1- Recurrent MI - clinical signs and symptoms of ischemia that are distinct from the 
presenting ischemic event and meeting at least 1 of the following criteria: 
1. Within 48 h after PCI:  
A. In patients with the baseline biomarkers values elevated and stable or falling, a rise of 
troponin values ≥ 20%. In addition, symptoms suggestive of myocardial ischemia or new 
ischemic electrocardiographic changes or angiographic findings consistent with a procedural 
complication or imaging demonstration of new loss of viable myocardium. 
B. Patients with new, significant Q waves in at least 2 contiguous leads of an ECG that were 
not present with the presenting ischemic event. 
C. Stent thrombosis associated with MI detected by coronary angiography or autopsy in the 
setting of myocardial ischemia and with a rise and/or fall of cardiac biomarker values with at 
least 1 value above the 99th percentile URL. 
2. Within 48 h after CABG: A CABG-related MI defined by elevation of cardiac biomarker 
values 10 times the 99th percentile URL in patients with normal baseline troponin values (99th 
percentile URL) plus either new pathological Q waves or new LBBB or angiographically 
documented new graft or new native coronary artery occlusion or imaging evidence of new 
loss of viable myocardium or new regional wall motion abnormality. Patients with cardiac 
biomarkers above the ULN before CABG with the increase in biomarkers ≥ 20% above the 
most recent value associated with symptoms/signs of myocardial ischemia were coded as 
reinfarction.  
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3. Spontaneous (before or without subsequent revascularization, > 48 h after PCI, and/or after 
CABG): new, significant Q waves in at least 2 contiguous leads of an ECG that were not 
present with the presenting ischemic event and/or an increase in CK-MB or troponin above 
the 99th percentile ULN, which is at least ≥ 20% above the most recent value in patients 
whose most recent cardiac markers drawn before reinfarction were normal [1]. 
2 - Cardiogenic shock - occurring after primary PCI, sustained, lasting > 30 min. episode of 
decrease in blood pressure (hypotension) with SBP <80 to 90 mmHg and/or CI <2.2L/min/m2, 
associated with peripheral hypoperfusion, manifested clinically by alteration in mental status, 
cooling of the extremities and decreased urine output, determined to be secondary to cardiac 
dysfunction and/or by requirement for parenteral inotropic or vasopressor agents or 
mechanical support (e.g., IABP, extracorporeal circulation, VADs) to maintain blood pressure 
and cardiac index above those specified levels [1]. 
3 - Cardiac arrest with successful resuscitation - sudden loss of mechanical heart function 
occurring after effective PCI procedure, characterized by the absence of the patient's response 
to stimuli, palpable pulse and/or apnea in the mechanism of ventricular fibrillation, pulseless 
ventricular tachycardia, asystole or pulseless electrical activity, requiring cardiopulmonary 
resuscitation. 
4 – Urgent PCI – urgent need for coronary angioplasty for presumed culprit lesion(s) 
suggested by increasing signs and symptoms of angina, documented ischemia in resting ECG 
recordings or induced by exercise stress test or angiographic evidence of new or worse ≥ 70% 
lesion and/or thrombus in an epicardial coronary artery that is believed to be responsible for 
the myocardial ischemic symptoms/signs [2]. 
5 - Urgent CABG – urgent need for coronary artery bypass grafting surgery in the case of 
documented ischemia and multi-vessel coronary artery disease evidence on coronary 
angiography requiring surgical revascularization as the only modality of treatment. 
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6 – Heart failure event/pulmonary edema –  episode of acute heart failure presenting 
clinically as pulmonary edema caused by a sudden deterioration of left ventricular function 
determined on the basis of signs and symptoms, objective diagnostic tests, requiring initiation 
or intensification of pharmacotherapy specifically for acute HF, including intravenous diuretic 
or vasoactive agents (e.g., inotrope, vasopressor, or vasodilator) or mechanical or surgical 
intervention [3]. 
7 - Stroke/TIA – documented sudden episode of focal neurological dysfunction of CNS 
lasting < 24 hours (Transient Ischemic Attack) or ≥ 24 hours or until death (stroke) 
attributable to ischemic etiology (TIA, ischemic stroke) or hemorrhagic etiology 
(intracerebral hemorrhage), based on pathological, imaging, or other objective evidence of 
cerebral, spinal cord, or retinal focal ischemic or hemorrhagic injury in a defined vascular 
distribution and other etiologies excluded [4]. 
8 - Cardiovascular death – a death due to immediate consequences of MI occurring within 
30 days of MI and invasive procedure (heart failure, stroke, complications of invasive 
procedure, cardiovascular haemorrhage) and distant >30 days after MI (acute MI, heart 
failure, stroke, sudden cardiac death, death due to other cardiovascular causes) [2]. 
---- 
Thromboxane measurements (detailed) 
Aliquoted urine samples were stored not longer than 6 months. After thawing on ice, 
creatinine concentration was measured using Vitros 350 Chemistry System (Ortho Clinical 
Diagnostics, Neckargemuend, Germany). Aliquot of urine (0.5 mL) was added deuterated and 
chemically identical internal standard (9S,15S-dihydroxy-11-oxo-thromboxa-5Z, 13E-dien-1-
oic acid (11-dehydro-TXB2-d4, 1 ng; Cayman Chemical Co., Ann Arbor, MI, USA). Next, 
the sample was acidified using acetic acid to pH 3.5 and extracted twice with equal volume of 
methyl-tert-butyl ether:methanol (8:2 v/v). Following extraction, the organic phase was 
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pooled and evaporated at 37°C under nitrogen. Before analysis, extracted sample was 
dissolved in methanol (50 microL). High performance liquid chromatography – tandem mass 
spectrometry (HPLC-MS/MS) measurements were done using HPLC equipped with 
autosampler (Shimadzu Sil-2-AC, Shimadzu Scientific Instruments, Inc. Columbia, MD, 
USA) and mass spectrometer (Qtrap 4000, Applied Biosystems, Foster City, CA, USA) with 
electrospray ion source and operating in multiple reaction monitoring negative ionization 
mode (MRM). Ten microL of the sample extract was injected on reverse phase column 
(Zorbax Eclipse XDB C-18, Agilent Technologies, Inc. Santa Clara, CA, USA) stabilized 
thermally at 37°C and eluted using a linear gradient of acetonitrile/water/acetic 
acid/isopropranol as published previously (ref.17). Urinary content of 11-dehydro-TXB2 was 
calculated using a stable isotope dilution method from area under peaks of 11-dehydro-TXB2 
(monitored 367-171 m/z ions pair) to the area under the peak of internal deuterated standard 
(monitored 371-165 m/z ions pair). Results were expressed in picograms per mg creatinine. 
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Supplemental Tables 
 
 
Table S1. The incidence of MACE and cumulative MACE during hospitalization, at 1-
month and 1-year follow-up. 
 
Major adverese cardiovascular events  
(MACE) 
During 
hospitaization 
n (%) 
After 1 month 
n (%) 
After 1 year 
n (%) 
1- Subsequent MI 0  (0%) 
10  
(5.8%) 
12  
(7.1%) 
2- Cardiogenic shock 6  (3.3%) 
2  
(1.2%) 
4  
(2.4%) 
3- Cardiac arrest with succesfull resuscitation  9  (5.0%) 
2  
(1.2%) 
7  
(4.1%) 
4- Urgent PCI 4  (2.2%) 
9  
(5.2%) 
10  
(5.9%) 
5- Urgent CABG  7 (3.9%) 
2 
(1.2%) 
3 
(1.8%) 
6- Heart failure event/pulmonary edema 12 (6.7%) 
3 
(1.7%) 
1 
(0.6%) 
5- Stroke/TIA 1  (0.6%) 
2  
(1.2%) 
2 
(1.2%) 
6- Cardiovascular death 4  (2.2%) 
1  
(0.6%) 
9 
(5.3%) 
Cumulative MACE 27*  (15.0%) 
42*  
(24.3%) 
60*  
(35.5%) 
 
* Cumulative MACE during hospitalization, at 1-month and 1-year follow-up do not add up because one patient 
could have more than one adverse cardiovascular event. Cumulative MACE assessment during hospitalization 
was performed for 180 patients, after 1 month for 173 (4 patients died during hospitalization and 3 patients were 
lost to follow-up). Cumulative MACE assessment after 1 year was performed for 169 patients (5 patients died 
and 6 patients were lost to follow-up). 
 
At 1-year follow-up the composite MACE appeared in 60 patients (35.5%) and in this group 
14 patients died (7.8%). 
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Figure S1.  Association of hs-CRP with quartile distribution of log-transformed 11-dehydro-
TXB2 
Footnotes: The average (bars) and SD (whiskers) of 11-dehydro-TXB2 quartile distribution on admission 
expressed in log-transformed values in association with hs-CRP. Ranges of log 11-dehydro-TXB2 quartiles are 
as follows: Q1- <6.85; Q2- 6.85-6.39;  Q3- 7.40-8.01; Q4- >8.01 [pg/mg creatinine]. 
Abbreviations: hs-CRP – high sensitive C-reactive protein 
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Figure S2. ROC curve for 11-dehydro-TXB2 on admission as a biomarker of cumulative 
MACE occurrence one year post-AMI in univariate analysis. 
 
 
Abbrevations: AUC – area under the curve. 
The cut-off point for natural logarithm of 11-dehydro-TXB2 was assumed 7.7 (pg/mg creatinine), with area 
under the curve (AUC) of 0.649  (specificity of 73.13% and sensitivity of 54.9%). 
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Supplementary Data (Data S1) 
 
Mathematical formula based on multivariate analysis to calculate the chance and probability of 
cumulative MACE occurrence 1 year post-AMI: 
 
chance = exp (0,978·LVEFhosp + 2,476·DM + MVD + 1,581·log 11-dehydro-TXB2hosp ) 
 
Abbreviations: 
− LVEFhosp – LVEF on admission [%] 
− DM (diabetes mellitus) = 1  for diabetic patients, 0 for non-diabetic patients 
− MVD (multivessel disease) = 0 for patients with 1-vessel disease; MVD = 
4.671 for 2-vessel disease and  MVD = 9.141 for 3-vessel disease 
− log-11-dehydro- TXB2 hosp – log of 11-dehydro-TXB2 on admission [pg/mg 
creatinine] 
 
Footnote:   probability = chance / (1 + chance) 
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